Topoisomerase IIα and other drug resistance markers in advanced non-small cell lung cancer

This publication has 38 references indexed in Scilit:

• Analysis of M Phase-specific Phosphorylation of DNA Topoisomerase II
  Published by Elsevier ,1996
• MRP is frequently expressed in human lung-cancer cell lines, in non-small-cell lung cancer and in normal lung
  International Journal of Cancer, 1996
• DNA topoisomerase II mutations and resistance to anti‐tumor drugs
  BioEssays, 1995
• Drug Resistance-Associated Marker Lrp for Prediction of Response to Chemotherapy and Prognoses in Advanced Ovarian Carcinoma
  JNCI Journal of the National Cancer Institute, 1995
• A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung Cancer
  New England Journal of Medicine, 1994
• A simple method to attach a universal 50-bp GC-clamp to PCR fragments used for mutation analysis by DGGE.
  Genome Research, 1992
• Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170- and 180-kDa isozymes
  Experimental Cell Research, 1992
• Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II
  Journal of Molecular Biology, 1992
• Determinants of Response to the DNA Topoisomerase II Inhibitors Doxorubicin and Etoposide in Human Lung Cancer Cell Lines
  JNCI Journal of the National Cancer Institute, 1992
• Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.
  Journal of Histochemistry & Cytochemistry, 1981